Skip to main content
Top
Published in: Journal of Translational Medicine 1/2016

Open Access 01-12-2016 | Erratum

Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines

Authors: Silvia Boero, Anna Morabito, Barbara Banelli, Barbara Cardinali, Beatrice Dozin, Gianluigi Lunardi, Patrizia Piccioli, Sonia Lastraioli, Roberta Carosio, Sandra Salvi, Alessia Levaggi, Francesca Poggio, Alessia D’Alonzo, Massimo Romani, Lucia Del Mastro, Alessandro Poggi, Maria Pia Pistillo

Published in: Journal of Translational Medicine | Issue 1/2016

Login to get access

Excerpt

It has come the publisher’s attention that the original version of this article [1] unfortunately contained an error. In Table 3, first column, the FcγRIIA 131 H>R genotypes were incorrectly labelled. In particular, V/V should have read H/H, V/F should have read H/R and F/F should have read R/R. Please note that this correction does not change the genotype numerical values of FcγRIIA polymorphism. The correct Table 3 has been published as Table 1 in this Erratum.
Table 1
Genotypic and allelic frequencies of FcγRIIIA and FcγRIIA polymorphisms in breast cancer patients and healthy controls
Genotypes
n (%)
P *
Alleles
n (frequency)
NEO (n = 15)
MTS (n = 10)
CTR (n = 33)
NEO (2n = 30)
MTS (2n = 20)
CTR (2n = 66)
FcγRIIIA 158V>F
     
FcγRIIIA 158V>F
   
 V/V
4 (26.7)
3 (30.0)
6 (18.2)
0.741
 V
13 (0.43)
8 (0.40)
26 (0.39)
0.934
 V/F
5 (33.3)
2 (20.0)
14 (42.4)
 
 F
17 (0.57)
12 (0.60)
40 (0.60)
 
 F/F
6 (40.0)
5 (50.0)
13 (39.4)
           
 HWE
P = 0.213
P = 0.065
P = 0.522
           
FcγRIIA 131H>R
     
FcγRIIA 131H>R
   
 H/H
3 (20.0)
4 (40.0)
9 (27.3)
0.499
 H
14 (0.47)
10 (0.50)
35 (0.53)
0.843
 H/R
8 (53.3)
2 (20.0)
17 (51.5)
 
 R
16 (0.53)
10 (0.50)
31 (0.47)
 
 R/R
4 (26.7)
4 (40.0)
7 (21.2)
           
 HWE
P = 0.782
P = 0.058
0.845
           
Genotyping of FcγRIIIA 158V>F was performed by a newly developed PSQ method after pre-amplification of FcγRIIIA gene. Genotyping of FcγRIIA 131H>R was performed by T-ARMS PCR and SBT. Conventionally, the 158V>F variant corresponds to the G>T SNP [i.e. guanine corresponding to valine (V) and thymine corresponding to phenylalanine (F)] and the 131H>R SNP corresponds to the A>G SNP [i.e. adenine corresponding to histidine (H) and guanine corresponding to arginine (R)]
Comparison of FcγR genotypic and allelic frequencies between patients and control subjects was estimated using the Pearson’s χ2 test (P* value) and the Fisher’s test (P° value), respectively. Statistical significance: P < 0.05
NEO neoadjuvant, MTS metastatic, CTR controls, HWE Hardy–Weinberg equilibrium. HWE was tested by the Pearson’s χ2 test (P < 0.05 indicates lack of HWE)
Literature
1.
go back to reference Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F, D’Alonzo A, Romani M, Del Mastro L, Poggi A, Pistillo MP. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J Transl Med. 2015;13:324.PubMedCentralCrossRefPubMed Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F, D’Alonzo A, Romani M, Del Mastro L, Poggi A, Pistillo MP. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J Transl Med. 2015;13:324.PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
Authors
Silvia Boero
Anna Morabito
Barbara Banelli
Barbara Cardinali
Beatrice Dozin
Gianluigi Lunardi
Patrizia Piccioli
Sonia Lastraioli
Roberta Carosio
Sandra Salvi
Alessia Levaggi
Francesca Poggio
Alessia D’Alonzo
Massimo Romani
Lucia Del Mastro
Alessandro Poggi
Maria Pia Pistillo
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2016
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-016-0779-y

Other articles of this Issue 1/2016

Journal of Translational Medicine 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.